Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › tamoxifen

tamoxifen

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of tamoxifen

66 trials tracked of tamoxifen: 22 in phase 3 or 4 and 11 with published results. The most-cited published study has 1022 citations.

66Trials tracked
22Phase 3 & 4
0Recruiting
11With published results
Phase distribution
Phase 4 6 Phase 3 16 Phase 2 36 Phase 1 4 Other / NA 4
  1. Phase 3 Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid Completed · 1,022 cited
  2. Phase 3 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Completed · 748 cited
  3. Phase 3 Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Completed · 727 cited
  4. Phase 3 Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Completed · 269 cited
  5. Phase 3 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Completed · 225 cited
  6. Phase 3 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed · 197 cited
Show 44 more trials
  1. Phase 3 Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer Completed · 129 cited
  2. Phase 3 Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02 Completed · 39 cited
  3. Phase 4 Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users Completed · 21 cited
  4. Phase 4 Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS) Completed · 14 cited
  5. Phase 3 Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer Completed · 11 cited
  6. Phase 4 Tamoxifen for the Treatment of Unfavorable Bleeding in Contraceptive Implant Users Completed
  7. Phase 4 Effects of Tamoxifen in Premenopausal Women With Benign Breast Disease Not at High-Risk of Developing Breast Cancer Completed
  8. Phase 4 Open-Label Drug Interaction Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) 100mg On The Pharmacokinetics Of Tamoxifen When Coadministered To Healthy Post-Menopausal Female Subjects Completed
  9. Phase 4 Liver Safety Under Upfront Arimidex vs Tamoxifen Completed
  10. Phase 3 Cognition in the Study of Tamoxifen and Raloxifene Completed
  11. Phase 3 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ Completed
  12. Phase 3 Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer Completed
  13. Phase 3 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed
  14. Phase 3 Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment Completed
  15. Phase 3 Adjuvant Oophorectomy and Tamoxifen in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Completed
  16. Phase 3 A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer Completed
  17. Phase 2 Everolimus Combined With Anti-estrogen Therapy in Hormone-Receptor-Positive HER-2 Negative Advanced Breast Cancer Completed
  18. Phase 2 Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Completed
  19. Phase 2 Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer Completed
  20. Phase 2 Neoadjuvant Tamoxifen in Locally Advanced Breast Cancer in a Low/Middle Income Country Completed
  21. Phase 2 Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension Completed
  22. Phase 2 Safety and Efficacy Study of Creatine and Tamoxifen in Volunteers With Amyotrophic Lateral Sclerosis (ALS) Completed
  23. Phase 2 Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor Completed
  24. Phase 2 Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients With Bone Metastasis Completed
  25. Phase 2 Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer Completed
  26. Phase 2 A Study of Palbociclib in Combination With Fulvestrant or Tamoxifen as Treatment for Metastatic Breast Cancer Completed
  27. Phase 2 Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women) Completed
  28. Phase 2 Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance Completed
  29. Phase 2 Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ Completed
  30. Phase 2 Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen Completed
  31. Phase 2 Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer Completed
  32. Phase 2 TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer Completed
  33. Phase 2 Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% Completed
  34. Phase 2 Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors Completed
  35. Phase 2 Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen Completed
  36. Phase 2 Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer Completed
  37. Phase 2 Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery Completed
  38. Phase 2 Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA Completed
  39. Phase 2 Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast Completed
  40. Phase 2 A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Completed
  41. Phase 2 Umbrella Trial of Subtype-Targeted Therapies in ER+/HER2- Breast Cancer Completed
  42. Phase 2 Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment Completed
  43. Phase 2 Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Completed
  44. Phase 2 Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Completed

Showing the 50 most-cited and recently-updated of 66 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Tamoxifen reduces distant recurrence risk by HR 0.37 in PR-positive postmenopausal breast cancer
Oncology RCT
Tamoxifen reduces distant recurrence risk by HR 0.37 in PR-positive postmenopausal breast cancer Tamoxifen Shows Long Term Benefit for Specific Breast Cancer Types
This secondary analysis of a randomized controlled trial involving 559 postmenopausal patients with lymph node-negative, ER-positive/HER2-ne…
A 25-year follow up shows that tamoxifen may provide lasting protection against cancer recurrence for patients with specific hormone recepto…
Jul 15, 2026
Tamoxifen improves 20-year distant recurrence-free interval for Luminal A and B breast cancer
OB/GYN & Women's Health RCT
Tamoxifen improves 20-year distant recurrence-free interval for Luminal A and B breast cancer Tamoxifen reduces long-term breast cancer recurrence in specific subtypes
This secondary analysis of a randomized controlled trial involving 952 patients with estrogen receptor-positive and HER2-negative tumors fou…
A 20-year follow-up shows that tamoxifen significantly lowers the risk of distant cancer recurrence for patients with luminal A and B tumors…
Jul 8, 2026
Tamoxifen adjunct to corticosteroids shows no motor benefit in Duchenne muscular dystrophy extension study
Pediatrics RCT
Tamoxifen adjunct to corticosteroids shows no motor benefit in Duchenne muscular dystrophy extension study Does adding tamoxifen to standard treatment help boys with Duchenne muscular dystrophy?
A 48-week open-label extension of a phase 3 trial in 66 boys with DMD found no significant difference in motor function change between early…
Adding tamoxifen to standard steroid treatment did not improve motor function or slow disease progression in boys with Duchenne muscular dys…
Apr 3, 2026